Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Urology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Urology

Journal Scan / Research · August 20, 2013

Randomized Double-Blind, Active-Controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β(3)-Adrenoceptor Agonist, in Overactive Bladder

European Urology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Alan Wein MD, PhD(hon), FACS

Dana Weiss MD

European Urology
Randomized Double-Blind, Active-Controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β(3)-Adrenoceptor Agonist, in Overactive Bladder
Eur Urol 2013 Feb 01;63(2)296-305, CR Chapple, SA Kaplan, D Mitcheson, J Klecka, J Cummings, T Drogendijk, C Dorrepaal, N Martin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated